Research programme: cannabidiol therapeutics - ISA Scientific/Yissum/Hadasit/Kennedy Trust for Rheumatology Research

Drug Profile

Research programme: cannabidiol therapeutics - ISA Scientific/Yissum/Hadasit/Kennedy Trust for Rheumatology Research

Latest Information Update: 06 Jul 2016

Price : $50

At a glance

  • Originator Hadassah Medical Organization; Hebrew University of Jerusalem; The Kennedy Trust for Rheumatology Research
  • Developer Hadasit; ISA Scientific; The Kennedy Trust for Rheumatology Research; Yissum Research Development Company
  • Class Analgesics; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetes mellitus; Inflammation; Ischaemic heart disorders; Vascular disorders

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top